ClinicalTrials.Veeva

Menu

Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

T

TTY Biopharm

Status and phase

Unknown
Phase 2

Conditions

Metastatic Breast Cancer

Treatments

Drug: Lipo-Dox

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

To determine the overall objective response rate of pegylated liposomal doxorubicin (Lipo-Dox)combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.

Enrollment

47 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • histologically proved breast cancer with metastatic disease

Exclusion criteria

  • life expectancy less than 3 months.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems